prostate cancer – TechConnect Briefs

Dendrigraft Poly-L-lysine (d-PLL) Coated Gold Nanoparticles in Water for siRNA Delivery to Prostate Cancer Cells

Rahme K., Minassian G., Ghanem E., Souaid E., Guo J., O’Driscoll C.M., Holmes J.D., Notre Dame University (Louaize), LB

In this study we used dendrigraft poly-L-lysine (d-PLL) as a stabilising ligand for gold nanoparticles (AuNPs) in water. The d-PLL generation two (P2) with narrow molecular weight distribution of about 7 KD was obtained by [...]

Detection of Prostate-Specific Antigen (PSA) with an Ultra High Performance Electrode Modified with Sol-Gel Au Nanoparticles

Leung S.W., Mozneb S., Lai J.C.K., Assan D., Idaho State University, US

Prostate cancer is one of the leading cancer causing death in men, especially in western developed countries. Prostate-specific antigen (PSA) is one of the biomarker that can be used to diagnose prostate cancer, although using [...]

Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (–) prostate cancers

Jo H., Ban C., Pohang University of Science and Technology, KR

We have designed a dual-aptamer complex specific to both prostate-specific membrane antigens (PSMA) (+) and (–) prostate cancer cells. In the complex, an A10 RNA aptamer targeting PSMA (+) cells ¬¬and a DUP-1 peptide aptamer [...]

Landscape phage probes for PC3 prostate carcinoma cells

Jayanna P.K., Deinnocentes P., Bird R.C., Petrenko V.A., Auburn University, US

Cancer chemotherapy is complicated by a lack of selective drug targets. The use of liposomes as vectors for drug delivery has provided a route to selective accumulation of nanoparticles in the tumor interstitium due to [...]

Targeted Aptamer-Nanoparticles to Diminish Drug Resistance of Cancer Cells in vitro Study

Basto P., Alexis F., Levy-Nissenbaum E., Langer R., Farokzhad O., Massachusetts Institute of Technology, US

Using prostate cancer as a model, we report the drug release of pacitaxel and doxorubicin from aptamer-poly (D,L lactic co glycolic acid)-poly(ethylene glycol) (PLGA-PEG) nanoparticles used to target prostate-specific membrane antigen (PSMA), a well characterized [...]